Search research articles
Contact Us
Filters
Showing results (481-490 of 567) with videos related to
Page
of 57
Sort By:
Cell Reports
|
October 12, 2022
Steroid hormone catabolites activate the pyrin inflammasome through a non-canonical mechanism
Flora Magnotti, Daria Chirita, Sarah Dalmon, et al.
BJU International
|
April 2, 2020
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma
Sumanta K Pal, David F McDermott, Michael B Atkins, et al.
Journal for Immunotherapy of Cancer
|
March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 4, 2024
Characterization of Genetic Landscape and Novel Inflammatory Biomarkers in Patients With Adult-Onset Still's Disease
Joanne Topping, Leon Chang, Fatima Nadat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2020
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab <b>+</b> Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma
Michael B Atkins, Brian I Rini, Robert J Motzer, et al.
Journal for Immunotherapy of Cancer
|
November 12, 2020
Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma
Abhishek Tripathi, Edwin Lin, Wanling Xie, et al.
Nature Communications
|
August 31, 2016
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J Wallin, Johanna C Bendell, Roel Funke, et al.
Cancer Immunology Research
|
November 24, 2020
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1
Rupal S Bhatt, Abdulla Berjis, Julie C Konge, et al.
Nature Communications
|
October 31, 2015
Allelic variation contributes to bacterial host specificity
Min Yue, Xiangan Han, Leon De Masi, et al.
Page
of 57
Search research articles
Search
Showing results (481-490 of 567) with videos related to
Sort By:
Page
of 57
Cell Reports
|
October 12, 2022
Steroid hormone catabolites activate the pyrin inflammasome through a non-canonical mechanism
Flora Magnotti, Daria Chirita, Sarah Dalmon, et al.
BJU International
|
April 2, 2020
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma
Sumanta K Pal, David F McDermott, Michael B Atkins, et al.
Journal for Immunotherapy of Cancer
|
March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 4, 2024
Characterization of Genetic Landscape and Novel Inflammatory Biomarkers in Patients With Adult-Onset Still's Disease
Joanne Topping, Leon Chang, Fatima Nadat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2020
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab <b>+</b> Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma
Michael B Atkins, Brian I Rini, Robert J Motzer, et al.
Journal for Immunotherapy of Cancer
|
November 12, 2020
Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma
Abhishek Tripathi, Edwin Lin, Wanling Xie, et al.
Nature Communications
|
August 31, 2016
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J Wallin, Johanna C Bendell, Roel Funke, et al.
Cancer Immunology Research
|
November 24, 2020
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1
Rupal S Bhatt, Abdulla Berjis, Julie C Konge, et al.
Nature Communications
|
October 31, 2015
Allelic variation contributes to bacterial host specificity
Min Yue, Xiangan Han, Leon De Masi, et al.
Page
of 57